Status:
WITHDRAWN
Use of the Insulin Pump in Cystic Fibrosis Patients With Impaired Glucose Tolerance or CFRD and in Type 1 Diabetes Patients.
Lead Sponsor:
University of Texas Southwestern Medical Center
Conditions:
Cystic Fibrosis Related Diabetes
Eligibility:
All Genders
12-32 years
Phase:
NA
Brief Summary
We hypothesize use of the insulin pump will improve body weight, lean body mass, whole body protein turnover, hepatic glucose production (HGP), and blood sugar control in CF patients with impaired glu...
Detailed Description
The insulin pump provides standard treatment for many patients with type 1 and type 2 diabetes and has been proven to be more effective in blood glucose control than subcutaneous injections. However, ...
Eligibility Criteria
Inclusion
- Cystic fibrosis patients aged 12-32 years
- Impaired glucose tolerance or CFRD defined as fasting blood glucose (FBG) and post-prandial blood glucose (pp) equal to: FBG \<126 and pp 151-200, or FBG \<126 and pp \>200, or FBG \>126 and pp \>200.
- Type 1 diabetes control patients aged 12-32 years.
Exclusion
- Colonization with Burkholderia cepacia
- currently on corticosteroid medication
- pregnant
- medically unstable
- Unable to understand the insulin pump directions
Key Trial Info
Start Date :
February 2 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 2 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00287456
Start Date
February 2 2006
End Date
February 2 2006
Last Update
January 10 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Medical Center of Dallas
Dallas, Texas, United States, 75390